Cancer Advances, Inc. announces new publication: "Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment", in the journal...

Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy.

Polyclonal Antibody Stimulator (PAS) monotherapy elicits both a humoral and a cellular immune response when used in immune competent mice bearing pancreatic tumors.

PAS monotherapy produced a marked T-cell activation and influx of CD8+ lymphocytes intoA pancreatic tumors.

When PAS was given in combination with PD-1 Ab, tumors had less fibrosis, fewer inhibitory regulatory T lymphocytes (Tregs) and fewer tumor-associated macrophages.

This research provided the basis for a poster presentation at ASCO GI in January 2019.

DURHAM, N.C., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, today announced a new publication in the journal: Cancer Immunology, Immunotherapy.A 
The researchers set out to determine whether vaccination with Cancer Advancesa?? anti-gastrin cancer vaccine, PAS (Polyclonal Antibody Stimulator) induces a gastrin-dependent T-cell response in immune competent mice with pancreatic cancer. The study also examined the impact of PAS monotherapy and PAS combined with a PD-1 immune checkpoint antibody on pancreatic tumor growth, and the tumor microenvironment.Gastrin is a digestive hormone known to have growth-promoting effects in pancreatic and other gastrointestinal cancers.A  Prior clinical research with PAS demonstrated that blocking gastrin led to an increase in overall survival in patients who produced an antibody response following vaccination. A A Pancreatic cancer has one of the lowest five-year survival rates of any cancer.A  Patients are often diagnosed in late stages of the disease once the cancer has already spread outside the pancreas.A  In addition, the tumora??s microenvironment is densely fibrotic and resistant to the bodya??s immune defenses, chemotherapy, and immune therapy.A In this study, male mice were exposed to pancreatic cancer cells and then randomized to one of six treatment groups: placebo, 2 different doses of PAS monotherapy, one dose of PD-1 antibody monotherapy, and combination PAS/PD-1 antibody at the 2 different doses of PAS. After four weeks researchers measured the impact of treatment on tumor volume, intra-tumor fibrosis, and immune cell activity in the tumor environment.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2022    »